People

The People Running This Company

Governance grade: C-. Andrew Dudum owns roughly 7% of the economics but commands 88% of the votes through super-voting Class V shares. Every other governance fact on this page — the deep, qualified board, the stock-ownership guidelines, the clawback policy, the anti-pledging rules — lives downstream of that one number. Add $43M of insider selling in 13 months, zero insider buying, $4.1M of related-party payments to the COO's spouse's company, and a $24.6M CEO pay package at a company that lost money on a GAAP basis in 2024, and the picture is "high-conviction founder play, buy the chairman not the business."

1. The People Running This Company

Dudum is the whole story. He founded Hims inside his own venture studio (Atomic Labs) at 27, took it public via SPAC at 31, and now runs a $6B-revenue company at 37 with no check on his authority. The three lieutenants who actually build the business — Okupe (finance), Chi (growth), Boughton (legal) — are capable but have been at the company less than five years each. The COO seat has turned over twice in 2025 alone (Baird out May 2025, Kabbani out November 2025, Chi promoted in), which is unusual turbulence for a company of this size at a moment of peak regulatory scrutiny.

2. What They Get Paid

Pay is aggressive but not outrageous by telehealth-peer standards. The composition is what matters: 92% of Dudum's package is equity, tied in large part to stock-price performance hurdles ($38.31 vesting trigger was hit in Feb 2025). The 200% bonus payout for 2024 is defensible — revenue came in at 112% of target and adjusted EBITDA at 153% of target. The $180K "home security reimbursement" inside "All Other Compensation" is the one line that sticks out as a personal perk; most peer CEOs at this size don't get one.

What drags the optics: Dudum's economic package is 43x the median employee, he didn't take an option grant in 2024 (only RSUs/PRSUs), and the pay committee is chaired by Andrea Perez, a first-time public-company compensation chair whose independence lives within a board Dudum controls via a vote he can never lose.

3. Are They Aligned?

Ownership and control

One share of Class V equals 175 votes of Class A. Dudum holds every Class V share (via his trusts). The practical result is that BlackRock and Vanguard — who together own 19% of the economics — control roughly 2.5% of the votes. Every share outside the founder's trusts is voting in an advisory capacity. This is among the most extreme voting-rights imbalances in the entire US mid-cap universe.

A dormant but worth-noting provision: if Class V ever converts to Class A, the board automatically becomes classified into three staggered classes. In other words, if Dudum ever loses voting control he has pre-armed the company with a takeover defense.

Insider buying vs. selling

Not a single insider bought a share in the open market during the 13 months on record. Over the same window insiders sold $43.2M, with the heaviest activity in September–October 2025 when the stock printed all-time highs above $60. The CFO sold $11.6M in two September days alone, mostly at $55-60; the same insider is still selling now at $25-30. Dudum sold $15.3M in two concentrated windows — 2025-09-16/17 and 2025-10-16 — entirely at $50-63, and has not sold since.

The pattern is what's disqualifying. Heavy, coordinated selling at local highs, followed by silence when the stock halved (after the Novo Nordisk breakup in June 2025 and the compounded-GLP-1 regulatory noise), then resumption of mid-sized CFO sales in April 2026. The data does not tag 10b5-1 plans explicitly, but the metronomic tranche pattern of Okupe's sales is consistent with a plan. Either way: when management was closest to a regulatory inflection, they took money off the table.

Dilution and equity cost

Equity awards to named officers in 2024 alone totaled $47.3M of stock grants on top of $24.6M of cash-and-perks. With SBC running at a multi-hundred-million-dollar annual rate and net income only modestly positive, essentially all GAAP profit is being returned to insiders via equity. Dilution is continuing: Dudum received 794,002 shares on 2026-02-23 and 413,844 more on 2026-03-11 as annual grants, with a Feb 2025 milestone already having vested another 1.6M performance options plus 162K RSUs.

Related-party transactions

The Vouched arrangement is the only material one, and it is sizable — $4.1M to a vendor controlled by the former COO's spouse is not a trivial sum. The company claims the contract is on market terms; the shareholder has to take that on faith because no comp comparison is disclosed. Atomic Labs is not listed as a related party, but Dudum's continued co-founder role there is a governance hair: any future commercial dealing between Hims and an Atomic portfolio company would be an obvious flag.

Skin-in-the-game score

• Control vs. capital (−): 88% of the votes against 7% of the economics is the textbook definition of misaligned voting rights.
• Buying behavior (−): Zero open-market purchases by any insider in the past two years.
• Selling behavior (−): $43M of selling concentrated at the all-time high.
• Ownership stock (+): Dudum does hold ~$500M+ of Hims stock outright; he is wealthy on paper through the same shares public holders own, so the downside scenario (stock going to $5) hurts him too.
• Ownership guidelines (+): 5x salary for CEO, 2.5x for execs, 5x cash retainer for directors — adopted July 2024, compliance achieved.
• Anti-hedging / anti-pledging (+): Explicitly prohibited in the insider-trading policy.

The founder is wealthy through the stock, which is a real alignment. But control without corresponding capital and a selling pattern that looks like peak-timing outweigh the stock-ownership box-checking.

4. Board Quality

On paper this is a strong board. David Wells (Netflix CFO for 8 years, now chairs Wise and sits on Trade Desk's audit committee) is an unusually heavyweight lead independent director for a $6B company. Kåre Schultz ran Teva Pharmaceutical — directly relevant to the branded-versus-compounded GLP-1 fight. Deb Autor spent 12 years at the FDA, including as Deputy Commissioner for Global Regulatory Operations — she is exactly the hire you'd make before a regulatory dust-up, although she also took a paid consulting arrangement that blurs her independence. Chris Payne ran DoorDash as COO. Toby Cosgrove ran Cleveland Clinic. This is a top-quartile slate of public-company expertise.

The problem is not expertise. It is power. When one person controls 88% of the vote, every independent director serves at the pleasure of that one person. Say-on-pay is advisory. Board elections are annual but uncontested. There is no conceivable vote that can go against Dudum. An entire board's worth of Netflix CFOs and FDA deputies cannot make the shareholder votes count.

5. The Verdict

What would make it a B: Dudum sunsets Class V voting after a defined period (a path Meta and Google have refused but Snap and some others have offered). Or the CFO completes his 10b5-1 program and insiders resume buying after the next regulatory shoe drops. Or the Vouched arrangement gets competitively re-bid and disclosed. Or the board formally separates the CEO and Chair.

What would take it to D: An SEC or FDA enforcement action tied to compounded GLP-1 marketing where the board cannot demonstrate it pushed back in real time. A material new related-party disclosure involving Atomic Labs. A repeat episode of fast, pre-inflection insider selling without a disclosed 10b5-1 trail.

The strongest positives: A genuinely qualified board (Netflix CFO, Teva CEO, FDA veteran, Cleveland Clinic CEO), robust policy infrastructure (clawback, anti-pledging, ownership guidelines), and a CEO-founder with meaningful personal wealth in the stock. Pay is high but performance-linked; the 2024 payout was earned by beating revenue and EBITDA targets.

The real concerns: Voting control without proportional economic ownership, $43M of insider selling concentrated at peak prices with zero buying, a $4.1M related-party vendor tied to a former executive, CEO-Chair combined and also chairing Nominating & Governance, and a COO seat that turned over twice in a single year during the company's most regulatory-sensitive chapter.

The one thing that would flip the grade: Dudum voluntarily agrees to sunset Class V super-voting rights at a fixed future date. Until then, this is a company where shareholders are along for the founder's ride — which is fine when the founder is executing, and extremely not fine when he isn't.